Shirish Gadgeel, MD, Discusses Key Takeaway From the 2024 World Conference on Lung Cancer
October 10th 2024Shirish Gadgeel, MD, discusses the promising results of the randomized phase 3 HARMONi-2/AK112-303 study comparing ivonescimab to pembrolizumab in PD-L1–positive advanced non-small cell lung cancer.
Watch
Increases in Pre-Term Birth Rates Observed in All Races, Higher Increases in Minority Groups
October 9th 2024The highest pre-term birth rates were consistently observed among those who were Black, American Indian or Alaska Native, or Native Hawaiian or other Pacific islander with public insurance.
Read More
Understanding the Basics of Study Analysis is Key to Evidence-Based Practice
October 9th 2024Despite its importance, after graduating from pharmacy school, many pharmacists likely experience a decline in confidence in their ability to appropriately evaluate studies and interpret statistical findings.
Read More
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC
October 8th 2024At the 2024 World Conference on Lung Cancer, Ana Baramidze, MD, PhD, presented 5-year outcomes of the trial, which investigated cemiplimab monotherapy in first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of 50% or greater.
Watch